Policy
Eli Lilly Stock Outlook: Potential $5,500 Target in 5 Years
Eli Lilly stock has seen a 376% total return over the past five years, driven by enthusiasm for its GLP-1 offerings like tirzepatide. While such explosive growth may not repeat, analysts suggest the pharmaceutical giant could still double in value in the next five years, potentially reaching over $5,500 per share.
pharmabiotechmanaged care
Investors looking at the pharmaceutical sector may monitor Eli Lilly (: ) for its continued growth potential in -1 therapies, despite expectations of moderating past performance.
